Literature DB >> 28818433

Dose-ranging design and analysis methods to identify the minimum effective dose (MED).

Yijie Zhou1, Su Chen2, Danielle Sullivan1, Yihan Li1, Ying Zhang1, Wangang Xie1, Hongtao Zhang1, Yuanyuan Tang3, Li Wang1, Alan Hartford1, Bo Yang4.   

Abstract

In dose ranging clinical trials, it is critical to investigate the dose-response profile and to identify a minimum effective dose (MED) to guide the dose selection for phase 3 confirmatory trials. Traditional dose ranging trials focus on pairwise comparisons between placebo and each investigational dose, while in recent years MCP-Mod (Multiple Comparison Procedures & Modeling) arose and gained popularity in the design and analysis of dose ranging trials. Comprehensive comparison between MCP-Mod and other methods have been made on continuous variables assuming a normal distribution. In this article, we extend the comparison to binary/binomial response variables. Via simulation, the rate of correct and incorrect MED identification are compared for Dunnett's test, trend test and MCP-Mod for a variety of underlying dose response profiles including both monotone and non-monotone dose responses and are compared under a large number of trial design settings. The precision of MED estimation using MCP-Mod is also evaluated comparing the design options of more dose levels and smaller sample size per dose versus fewer dose levels and larger sample size per dose.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dose response modeling; Dunnett's test; MCP-Mod; Minimum effective dose (MED); Trend test

Mesh:

Substances:

Year:  2017        PMID: 28818433     DOI: 10.1016/j.cct.2017.08.005

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  1 in total

1.  Beyond exposure-response: A tutorial on statistical considerations in dose-ranging studies.

Authors:  Glen Laird; Lei Xu; Meng Liu; Jin Liu
Journal:  Clin Transl Sci       Date:  2021-05-01       Impact factor: 4.689

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.